EXPERIMENTAL MATERIALS AND METHODS

Animals
Four individual animal experiments were performed. In experiments 1 and 2, sixteen 100 to 150 kg Holstein Friesian calves were used. Two animals (referred to later as inoculates) were selected at random, and were needle challenged intradermolingually (1) Following challenge the inoculates were kept in a separate box in the bio-secure isolation compound at Pirbright. Forty eight hours later two naïve animals were introduced to the inoculates and were challenged by direct contact exposure for 24 hrs. Challenge took place in closed boxes of dimensions 4.0 x 4.8 x 2.64 metres, with concrete floors.The inoculates were removed from the study and the animals exposed to infection by direct contact were used to attempt transmission to the remaining cattle, two, four and six days later for a period of 8 hrs each time. Following preliminary analysis of the data from these first two experiments additional attempted transmissions at day 8 were included in the experimental design, thus 4 additional animals were included in the final two experiments, 3 and 4.
During the challenge period the ventilation in the challenge boxes was turned off, raising the relative humidity to greater than 99%, (measured using a Fisher Scientific, Thermometer/Hygrometer, Traceable FB70257). In addition, a wall mounted fan was used to mix the air in the challenge boxes. The challenge model was optimised during pilot studies to ensure efficient transmission to recipients. During these pilot studies we tested a variety of challenge periods between donor and recipient animals, transmission was shown to occur during a two hour transmission period when the donors were at the peak of clinical signs.
Therefore, an 8 hour challenge period was selected for the main studies to provide increased opportunity for transmission to occur.
Sample size
For both ethical and logistic reasons, considerable attention was given to sample size calculation. Based on data from pilot studies, a sample size of 7 donors was expected to give just over 80% power to correctly identify the day of peak infectiousness. In the event, 8 were used, of which one did not become infectious. We note that each donor has associated both inoculated animals as sources of infection and recipient animals to test for infectiousness, giving a grand total of 44 cattle used (see above), thus making it a very substantial study given the requirement for high containment facilities. The results of the study (see main text)
are fully consistent with expectations and we conclude that this sample size was indeed appropriate for the aims of this study.
Clinical Scoring
A subjective scoring system (2) was modified and used to evaluate the development of disease up to 14 days post infection. The scoring system incorporated changes in rectal temperature and discriminated between new lesions and lesions that were healing. Hence, the profile of the clinical score plots reflected the induction and resolution of clinical signs.
Individual animals could therefore score a maximum of 22 points (the sum of scores from all feet was divided by 2 to prevent the score from being dominated by any foot lesions).
Sampling regime
Blood and nasal fluid samples were collected daily for 8 days post challenge and then every other day up to day 14. Oesophageal-pharyngeal fluid (OPF) samples were collected by probang cup from all the animals before challenge and thereafter from the donors daily for 8 days and then every other day up to day 12. OPF samples were also collected from recipient animals on days 7 and 14 post challenge. All samples were stored below − 70°C until processing. Nasal fluid and heparinised blood was stored for subsequent virus isolation and titration. Serum was stored for subsequent antibody (Ab) detection, nucleic acid extraction and analysis using quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR). OPF samples were stored for subsequent virus isolation and titration and qRT-PCR.
Virus isolation and titration
Virus was detected in the biological samples collected (heparinised blood, nasal fluid, OPF)
by virus isolation (VI) and titration in primary bovine thyroid (BTY) cell cultures (3).
Specificity for FMDV was confirmed by an antigen capture ELISA (4).
Quantitative real-time reverse transcription polymerase chain reaction
QRT-PCR analysis of serum and OPF samples was performed, using an automated robotic workstation for nucleic acid extraction and liquid handling (MagNA Pure LC, Roche), according to the methodology previously described (5,6). Reagents from a MagNA Pure LC Total Nucleic Acid Isolation Kit (Roche, UK) were used and total nucleic acid extracted from 200 µl of sample to a final elution volume of 50 µl. Automated reverse transcription procedures were performed as previously described incorporating homologous FMDV RNA standards (2,6,7). PCR amplification was performed on an MX3005P QPCR system 
Assay for FMDV specific antibodies
Serum samples were tested for the presence of antibodies to FMDV using a liquid phase blocking ELISA (LPBE) (4).
Interferon assay
Type-I interferon (IFN) biological activity was measured in serum samples from donor animals by using an Mx/chloramphenicol acetyltransferase (Mx/CAT) reporter gene assay (9). Table S1 contains a list of all of the virological, immunological and clinical variables measured during the course of the experiments. Examination of the structure of the data in Table S1 required that some variables be categorised for the purpose of statistical analysis. Table S2 lists the variables generated in the study and indicates how they were treated for the purpose of statistical analysis. In brief, the following variables were categorised as presence/absence: level of Viraemia, presence of FMDV antibodies in serum, and presence of all clinical signs including: mouth lesions, tongue lesions, foot lesions, nasal discharge and lameness. Variables quantity of live virus in nasal fluid, type 1 interferon in serum and quantity of live virus in the blood were assigned threshold levels based on expert opinion and/or breakpoints evident in the data. For all categorical variables an additional variable, 'onset', was generated. 'Onset' identifies the first detection of the variable; either on the day transmission was attempted or, in the previous 24 hours before transmission was attempted.
STATISTICAL METHODS: INDICATORS OF INFECTIOUSNESS
Data Management
Statistical Analysis
The data in this study were analysed using Nonmetric Multidimensional Scaling (NMS).
Nonmetric multidimensional scaling (NMS) was used to identify epidemiological variables associated with transmission events. NMS is a nonparametric ordination technique well suited to data that are non-normal or on arbitrary or discontinuous scales (10). The advantage of NMS is it avoids the assumption of linear relationships among variables. It uses the ranked distances, so tending to linearize the relationships between variables (10). A limitation is that the structure in the data is ignored, grouping within and among variation in the analysis and hence combining temporal and among subject variation in the ordination. (10) states that a final stress of 10-20 represents a fair ordination) and final instability was 0 with 66 iterations. Number of iterations is the number of steps that NMS performed to find the final solution (10). MRPP was performed to test the null hypothesis of no difference between the groups: transmission occurred and no transmission occurred.
Results show ( Table S3 ) that we can reject the null hypothesis of no difference between groups. The two groups occupy different regions of space as shown by the strong chancecorrelated within-group agreement (A) and significance level (p) ( Table S3 ).
The results of the NMS models are shown using 2D ordination graphs of the distance between sample units which approximates dissimilarity in FMD transmission potential.
Where appropriate, the mean ± 1 standard deviation bivariate intervals was added to discriminate between groups of interest, as in Fig. 1A of the main text which shows that transmission events were clustered to the right of the graph and non-transmission groups to the left. The bivariate scatterplot with bivariate data ellipse was drawn using the ELLIPSES macro (ellipses.sas, http://www.datavis.ca/sasmac/ellipses.html). Joint plots can also be generated to show the correlation of variables along either NMS axis 1 or NMS axis 2.
Variables used in the NMS analysis are shown as vectors; the direction indicates positive and negative correlation and the length along the axis (continuous variables only) depends on the strength of the correlation on that axis. As shown in Figure S1 , axis 1 and 2 from the NMS analysis provide an informative representation of the sequence of events that occur during FMDV infection and, crucially, how these relate to infectiousness.
ESTIMATING THE LATENT, INCUBATION AND INFECTIOUS PERIODS FOR FMDV Modelling approach
The data from the challenge experiments (Table S1 ) were used to define an indicator variable (δ ij ) such that δ ij =0 if transmission did not occur following the ith challenge by infected animal j (where the challenge started and stopped at (0) ij τ and
(1) ij τ hours post infection, respectively) and δ ij =1 if it did. The probability of transmission following the ith challenge by infected animal j (i.e. Pr(δ ij =1)) is given by,
where β is the transmission rate and,
(1)
is the time during the ith challenge for which animal j is infectious, and E j and I j are the latent and infectious periods for animal j, respectively.
Assuming complete data (i.e. the latent, incubation and infectious periods are fully observed), the likelihood for the challenge data can be written as,
where θ is the set of model parameters, E={E j }, C={C j } and I={I j } are the latent (E j ), incubation (C j ) and infectious (I j ) periods for the animals, f(E,C) is the joint probability density function (PDF) for the latent and incubation periods and g(I) is the PDF for the infectious period. Here we assumed the latent and incubation periods follow a bivariate lognormal distribution with parameters μ E , σ E , μ C , σ C and ρ. The infectious period was assumed to follow a log-normal distribution with parameters μ I and σ I .
For the (marginal) log-normal distributions, the mean (m i ) and variance (v i ) are related to the model parameters, such that,
where i denotes parameters relating to the latent (i=E), infectious (i=I) or incubation period (i=C). Furthermore, the correlation between the latent and incubation periods (ρ EC ) is given by,
where σ E , σ C and ρ are parameters from the bivariate log-normal distribution.
Bayesian framework
Complete data would allow the parameters to be estimated directly by finding those values which maximise the likelihood (S.3). In practice, however, the latent and infectious periods are unobserved, while the incubation period is known only to within a 24-hour window. To allow for this uncertainty the data were analysed in Bayesian framework in which the latent, infectious and incubation periods are treated as nuisance parameters.
A Bayesian approach requires two components, a likelihood function and prior information on the model parameters. The likelihood function is given by equation (S.3). Priors for the latent, infectious and incubation period parameters were derived from the results of a recent meta-analysis of the duration of infection stages for serotype O FMDV (11). More specifically, the prior for each parameter was assumed to follow a gamma distribution such that the expected values for the priors yielded log-normal distributions with the same mean and variance as the distributions for the latent, infectious and incubation periods in cattle (11) (see their table 2). Non-informative priors were used for the correlation parameter (Uniform (-1,1)) and the transmission rate (diffuse exponential with mean 100). All priors were assumed to be independent of one another.
To a constant of proportionality, the joint posterior density for the parameters is,
where L(•) is the likelihood given by equation (S.3) and ( ) π θ is the joint prior distribution for the parameters. The posterior density (S.4), is analytically intractable and, hence, must be explored using a computationally-intensive Markov chain-Monte Carlo (MCMC) approach to simulate samples from the joint posterior density.
The MCMC scheme used here is based on the Metropolis-Hastings algorithm (12,13), and generates a new parameter set, θ k+1 (transformed so that the parameters lie in the range ( , )), −∞ +∞ and latent (E
), infectious (I
) and incubation (C (k+1) ) periods from the previous ones (i.e. θ k , E
, I (k) and C (k) ) by applying the following three-step procedure:
(i) The latent and infectious periods were updated M times to produce a sequence of latent and infectious periods, E
, E
,…, E
, where
, and I
, I
,…, I (kM) , where
. At each step, m, the proposed latent and infectious periods, ′ E and , ′ I were generated as follows:
(a) with probability p an animal was selected at random and its latent period changed by adding to it a normal deviate with mean zero and variance 
Otherwise, they were rejected, so that 
) k + ′ = C C with probability,
( ; , , ) min 1,
Otherwise, they were rejected (i.e.
( 1) ( ) ). 
Otherwise, it was rejected (i.e.
1
).
By selecting a large value of M (here M=100) this formulation allows more effort to be expended in exploring the latent and infectious periods than the parameters and incubation periods. In addition, p was set to 0.5, though an alternative value could be chosen if it was more important to explore latent than infectious periods, for example. 
Estimation based on virus isolation data
Previous analyses of the latent, infectious and incubation periods for FMDV have been based on indirect measures of infectiousness, principally the detection of virus in blood or other samples taken from infected animals (11). Accordingly, further analyses were carried out in which the latent and infectious periods were estimated based on the results of (VI from blood, oesophageal-pharyngeal fluid (OPF) or nasal fluid (NF)) ( Table S1 ). In this case, the latent period was defined as the time at which virus was first isolated from the fluid, while the infectious period was defined as the interval between the first and last times at which virus was isolated (11). Sampling frequency meant, however, that there was uncertainty about the duration of these periods.
The likelihood for the virus isolation data can be written as,
where θ is the set of model parameters, f(E,C) is the joint PDF for the latent and incubation periods, g(I) is the PDF for the infectious period, E j is the first time point at which virus was isolated from animal j, C j is the first time point at which animal j showed clinical signs, (min) j I is the last time point at which virus was isolated from animal j and (max) j I is the time point at which the next (negative) sample was taken for animal j. As before, we assumed the latent and incubation periods follow a bivariate log-normal distribution with parameters μ E , σ E , μ C , σ C and ρ and the infectious period follows a log-normal distribution with parameters μ I and σ I .
Although we have complete information in this case (so the parameters could be estimated by maximum-likelihood methods), we analysed the data in a Bayesian framework with the likelihood (S.5), and the same priors as described above, for comparability with the analysis of challenge data. The MCMC scheme used to sample from the joint posterior distribution for the parameters generates a new parameter set, θ k+1 , from the previous one (i.e. θ k ) as follows.
A parameter set ( ) ′ θ was proposed by generating a new parameter set from the current one by adding a normal deviate with mean zero and variance 2 p σ to each parameter. The proposed parameter set was accepted (i.e.
)
k + ′ = θ θ with probability,
otherwise, it was rejected (i.e.
1
k k + = θ θ Again each chain was initialised by sampling parameters uniformly from appropriate ranges and the variance for the proposal distribution was tuned during burn-in to ensure an acceptance rate of between 20% and 40% for efficient sampling of the target distribution (14). Five chains, each of 120,000 iterations, were run, with the first 20,000 iterations discarded to allow for burn-in of the chain. The chains were then thinned (taking every one hundredth sample) to reduce autocorrelation amongst the samples.
Results
The marginal posterior densities for the model parameters are shown in Fig. 2A-D ; and summary statistics are presented in Table S4 .
COMPUTING THE PROPORTION OF TRANSMISSION THAT OCCURS BEFORE THE ONSET OF CLINICAL SIGNS General framework
In To extend this approach to allow for jointly distributed latent and incubation periods, we assume that the infectiousness of an animal τ days after infection following a latent period of E days is given by,
where γ is some function describing the change in infectiousness over time. If the latent (E) and incubation (C) periods have joint PDF, f(E,C), the expected infectiousness of an animal infected τ days previously is,
is the marginal PDF for the latent period. Moreover, the expected infectiousness that occurs prior to the onset of clinical signs is given by,
Consequently, the proportion of transmission that occurs before clinical signs develop is,
In the special case where the latent and incubation periods are independent, so that,
which is equivalent to the expression presented by Fraser et al. (17) (cf. equation (S.6)).
Model for FMDV
For the model used to describe the transmission of the FMDV in the challenge experiments (see section S4) the infectiousness function, (S.7), can be written as, 0 0 ,
where I is the duration of the infectious period (which has PDF g(I)). In this case, the expected infectiousness of an animal infected for τ days is given by,
Sensitivity analysis
Latin hypercube sampling (LHS) was used to explore the effect of the parameters influencing the proportion of transmission before the onset of clinical signs (θ), (S.10) (18). Uniform probability density functions were defined for the seven parameters influencing θ (mean and standard deviation for latent, infectious and incubation periods, correlation between latent and incubation period) with appropriate ranges selected for each (Table S4) . Each PDF was subdivided into 100 equiprobable intervals and then randomly sampled 100 times without replacement. The 100 samples from each PDF were then randomly permuted to yield 100 distinct parameter sets. For each parameter set, the corresponding value of θ was computed.
Replicated LHS was then implemented by repeating this procedure 50 times.
The results of the LHS show that the difference in mean latent and incubation periods (here expressed as mean incubation period minus mean latent period) is the principal parameter influencing the magnitude of θ, with θ being very low if the mean latent period is longer than the mean incubation period (Fig. S2A) . By contrast, the values of θ were typically much higher if the mean latent period is shorter than the mean incubation period (Fig. S2B) .
Moreover, values of θ are also higher for shorter mean infectious periods (Fig. S2C) or lower correlations between the latent and incubation periods (Fig. S2D ) (cf. also Fig. S2A,B) . The remaining parameters in Table S5 do not greatly influence θ (results not shown). Table S2 : 1, quantity of live virus in oesophageal-pharyngeal fluid (OPF); 2, FMDV genome copies in OPF; 3, quantity of live virus in the nasal fluid; 4, quantity of live virus in blood; 5, presence of FMDV genome copies in serum; 6, Type-1 interferon in serum; 7, rectal temperature; 8, change in rectal temperature; 9, presence of FMDV antibodies in serum; 10, presence of lesions in the mouth; 11, presence of lesions on the tongue; 12, presence of lesions on the feet; 13, presence of lameness; 14, presence of nasal discharge. 'O' prior to number indicates onset version of this variable. Figure S2 . Relationship between the proportion of transmission that occurs before clinical signs (θ) and the mean latent, infectious and incubation periods and the correlation between the latent and incubation periods. (A,B) Dependence of θ on mean infectious period and correlation between latent and incubation period when: (A) mean incubation period is shorter than mean latent period; or (B) mean incubation period is longer than mean latent period. (C,D) Dependence of θ on the mean incubation period minus the mean latent period and (C) mean infectious period and (D) correlation between latent and incubation periods. In each panel the colour of the points represents the value of θ, ranging from zero (black) to one (yellow) as indicated by the colour bar. In panels C and D the blue line indicates where the mean incubation and latent periods are equal, while the cyan symbol and lines indicate the posterior mean and interquartile range for parameters estimated from the FMDV challenge experiments (Table S4) . Results in are based on replicated Latin hypercube sampling. Table S1 . Experiment 1: detailed clinical, virus isolation, qRT-PCR and serum type-1 IFN data.
Presence of infectious virus (VI) in blood, oesophageal-pharyngeal fluid (OPF) and nasal fluid (NF) reported as log 10 TCID 50 per ml; Presence of viral RNA (qRT-PCR) in blood (serum) and OPF reported as log 10 copies of viral genome per ml; Serum: antibody titre (Ab) determined by LPBE; Type-1 IFN data reported as IU per ml of serum, $-Pre-challenge sample from day -−2; Appearance of clinical signs and score (Clin. signs), Temprectal temperature in °C, O.S.M. -lesions in oral cavity, snout or mouth area; Transmission events: C-challenge of the donor animal, T -transmission occurred, NT -no transmission occurred; nc -no sample collected, nsno sample available for analysis, nr -no data recorded, '+' -positive sample, '-' -negative sample.). N. discharge = nasal discharge Table S2 . List of the virological, immunological and clinical variables generated in this study and how they were treated in the NMS analysis. Type: C, category; Q, Quantitative. NA, not applicable.
Number* Description Type Category 1 † Quantity of live virus in OPF (log 10 TCID 50 /ml) Q NA 2 † Quantity of FMDV genome copies in OPF (log 10 copies/ml) Q NA 3¥ Quantity of live virus in the nasal fluid (log 10 TCID 50 /ml) C 1 = <4 log 10 TCID 50 /ml 2 = >4 log 10 TCID 50 /ml 4¥ Quantity of live virus in blood (log 10 TCID 50 /ml ) C 1 = <3 log 10 TCID 50 /ml 2 = >3 log 10 TCID 50 /ml 
